论文部分内容阅读
目的:观察细菌溶解产物OM-85BV对学龄前期儿童哮喘发作及其鼻部症状的疗效。方法:选取1~5岁轻中度哮喘慢性持续期患儿150例,采用Excel生成的随机数表分为试验组100例和对照组50例,所有患儿均接受丙酸氟替卡松吸入气雾剂吸入治疗(每次200μg,bid),其中试验组在丙酸氟替卡松吸入气雾剂吸入治疗基础上口服OM-85BV 3.5 mg/d,每月连用10 d,连续使用3个月为1个疗程,间隔3个月重复第2个疗程。治疗第3、6、9、12个月时进行随访,为期1年。结果:试验组患儿在治疗第12个月时喘息发作次数和在治疗第6个月起急性呼吸道感染(ARTI)的发作次数较对照组少,差异有统计学意义(P<0.05)。试验组各项鼻部症状在观察期内均有明显改善(P<0.05)。结论:OM-85BV能有效减少缓解期患儿哮喘急性发作的次数、改善其鼻塞和流涕症状以及儿童ARTI次数。
Objective: To observe the effect of bacterial lysate OM-85BV on asthma attacks and nasal symptoms in preschool children. Methods: A total of 150 children with chronic persistent mild-to-moderate asthma aged 1-5 years were enrolled in this study. The random number table generated by Excel was used to divide into 100 cases in trial group and 50 cases in control group. All children received fluticasone propionate inhalation aerosol (200 μg twice daily). The patients in the test group were treated with oral inhalation of fluticasone propionate inhalation aerosol inhalation therapy OM-85BV 3.5 mg / d for 10 days a month for three consecutive months as a course of treatment, Interval of 3 months repeat the second course of treatment. At the 3rd, 6th, 9th and 12th months of treatment, follow-up was carried out for 1 year. Results: The number of wheezing episodes and the number of episodes of acute respiratory infection (ARTI) at the 12th month of treatment in the experimental group were fewer than those in the control group. The difference was statistically significant (P <0.05). The nasal symptoms in the experimental group were significantly improved during the observation period (P <0.05). Conclusion: OM-85BV can effectively reduce the number of acute asthma attacks in children with remission, improve the symptoms of nasal congestion and runny nose and the number of ARTI in children.